HISHIPHAGEN should be used in patients that are pregnant or possibly pregnant only if the expected therapeutic benefits outweigh the possible risks. [Kidney malformation, etc., has been observed at massive doses of monoammonium glycyrrhizinate in animal studies (rats).]